Tirzepatide vs Liraglutide in Bone
Recruiting · NCT07094568 · Observational (researchers observe without assigning treatment) · Lead sponsor: National and Kapodistrian University of Athens
View the official record on ClinicalTrials.gov →What this trial is about
This prospective cohort study investigates the effects of tirzepatide versus liraglutide on bone turnover markers and body composition in adults with class 3 obesity, characterised by Body Mass Index (BMI) ≥40 kg/m². Participants will be followed for 6 months with assessments at baseline, 3 and 6. The primary outcome is the change in bone resorption marker C-terminal telopeptide of type I collagen (CTX) at 3 months. Secondary outcomes include changes in body weight, BMI, bone mineral density (BMD), and body composition. The study aims to clarify the differential impact of weight loss achieved through tirzepatide versus liraglutide on bone metabolism and body composition in adults with obesity.
Who can take part
Inclusion criteria
- Adults aged between 30 and 65 years
- BMI ≥40 kg/m²
Exclusion criteria
- Type 2 Diabetes Mellitus (T2DM) and type 1 Diabetes Mellitus (T1DM)
- Chronic kidney disease
- Liver failure
- Heart failure
- Malignancy coexistence
- Previous bariatric or gastrointestinal surgery involving intestinal bypass
- Uncontrolled hypo/hyperthyroidism
- Uncontrolled hypo/hyperparathyroidism
- Pregnancy and lactation
- Recent fracture (within 2 years)
- Rare Metabolic Bone Diseases (e.g., Paget's disease of bone, fibrous dysplasia, osteopetrosis)
- Inflammatory arthritis
- Medications which can affect bone markers: bone-anabolic agents, antiresorptive agents, antiandrogenic agents, vitamin K antagonists, antipsychotic agents, contraceptives, glucocorticoids (oral), methotrexate, thiazides, aromatase inhibitors etc)
- Hemolytic anemia
Where it is running
1 location listed.
- Laiko General Hospital - Athens, Attica, Greece